Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia
Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…A novel phenotype of amyloid precursor protein (APP) mutation presenting with dementia, and symptoms of both progressive supranulcear palsy (PSP) and multisystem atrophy (MSA)
Objective: To describe the novel phenotype of a patient with an amyloid precursur protein (APP) mutation presenting with dementia and symptoms of both progressive supranulcear…Heart rate variability to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment
Objective: We aimed to determine whether heart rate variability (HRV) can aid in the differentiation of DLB from AD at the MCI stage. Background: Mild…Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson’s disease
Objective: To investigate the role of APOE, MAPT, COMT, SNCA and GBA genes in both striatal dopaminergic denervation and the development of dementia in Parkinson's…How accurate is the prediction of driving ability in a Parkinson’s clinic setting?
Objective: To determine whether routine clinical assessment (motor examination, cognitive assessment and global clinical impression) accurately predicts the ability of People with Parkinson's (PwP) to…Survey of prodromal symptoms of Parkinson’s disease in Japan
Objective: To reveal prodromal symptoms at a public seminar for PD via questionnaires. Background: How to select subjects with PD for disease modify therapy in…Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease
Objective: 1) To determine serum urate and homocysteine concentration at baseline, 18 and 36 months in control and PD participants. 2) To determine if urate…Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease
Objective: We sought to determine: a) the ability of TYM to discriminate between PD patients with and without cognitive deficits b) equivalence between MoCA scores…Neuro-cognitive domain related to conversion of Parkinson’s disease dementia
Objective: To identify neurocognitive domain and mild cognitive impairment (MCI) subtype associated with conversion from non-demented patients with Parkinson's disease (PD) and PD-MCI to dementia…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 33
- Next Page »